205 related articles for article (PubMed ID: 11924776)
1. Effects of buprenorphine on immunogenicity and protective efficacy in the guinea pig keratoconjunctivitis model (Sereny test).
Hanson CE; Ruble GR; Essiet I; Hartman AB
Comp Med; 2001 Jun; 51(3):224-9. PubMed ID: 11924776
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of butorphanol tartrate and buprenorphine hydrochloride on the inflammatory reaction of the Sereny Test.
Swearengen JR; Cockman-Thomas RA; Davis JA; Weina PJ
Lab Anim Sci; 1993 Oct; 43(5):471-5. PubMed ID: 8277729
[TBL] [Abstract][Full Text] [Related]
3. Shigellosis.
Niyogi SK
J Microbiol; 2005 Apr; 43(2):133-43. PubMed ID: 15880088
[TBL] [Abstract][Full Text] [Related]
4. [Experimental model of keratoconjunctival infections in the study of immunity against Shigella].
Cefalù M; Puglisi C
G Mal Infett Parassit; 1972 Apr; 24(4):281-9. PubMed ID: 5050309
[No Abstract] [Full Text] [Related]
5. Correlation between Congo red binding as virulence marker in Shigella species and Sereny test.
Meitert T; Pencu E; Ciudin L; Tonciu M; Mihai I; Nicolescu S
Roum Arch Microbiol Immunol; 1991; 50(1):45-52. PubMed ID: 1802051
[TBL] [Abstract][Full Text] [Related]
6. Development of a new guinea-pig model of shigellosis.
Barman S; Saha DR; Ramamurthy T; Koley H
FEMS Immunol Med Microbiol; 2011 Aug; 62(3):304-14. PubMed ID: 21539623
[TBL] [Abstract][Full Text] [Related]
7. Development of prophylactic recombinant HPV58-attenuated Shigella live vector vaccine and evaluation of its protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model.
Li W; Liu H; Yang X; Zheng J; Wang Y; Si L
Acta Biochim Biophys Sin (Shanghai); 2009 Feb; 41(2):137-45. PubMed ID: 19204831
[TBL] [Abstract][Full Text] [Related]
8. Shigellosis: the current status of vaccine development.
Kweon MN
Curr Opin Infect Dis; 2008 Jun; 21(3):313-8. PubMed ID: 18448978
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial.
McKenzie R; Walker RI; Nabors GS; Van De Verg LL; Carpenter C; Gomes G; Forbes E; Tian JH; Yang HH; Pace JL; Jackson WJ; Bourgeois AL
Vaccine; 2006 May; 24(18):3735-45. PubMed ID: 16095766
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of pathogenicity tests for Shigella spp. and enteroinvasive Escherichia coli strains.
Cristea D; Ceciu S; Chitoiu DT; Bleotu C; Lazăr V; Chifiriuc MC
Roum Arch Microbiol Immunol; 2009; 68(1):44-9. PubMed ID: 19507627
[TBL] [Abstract][Full Text] [Related]
11. [Construction of prophylactic recombinant HPV58-attenuated Shigella vector live vaccine and evaluation of its protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model].
Li WS; Liu HL; Zhang YT; Yang XF; Wang YL; Si LS
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Dec; 23(12):1163-6. PubMed ID: 18062891
[TBL] [Abstract][Full Text] [Related]
12. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
13. Experimental keratoconjunctivitis (Sereny) assay.
Kopecko DJ
Methods Enzymol; 1994; 235():39-47. PubMed ID: 8057912
[No Abstract] [Full Text] [Related]
14. Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains.
Hartman AB; Powell CJ; Schultz CL; Oaks EV; Eckels KH
Infect Immun; 1991 Nov; 59(11):4075-83. PubMed ID: 1937767
[TBL] [Abstract][Full Text] [Related]
15. Comparison of alkaline phosphatase-conjugated oligonucleotide DNA probe with the Sereny test for identification of Shigella strains.
Panda CS; Riley LW; Kumari SN; Khanna KK; Prakash K
J Clin Microbiol; 1990 Sep; 28(9):2122-4. PubMed ID: 2229395
[TBL] [Abstract][Full Text] [Related]
16. [Immunosuppressive properties of virulent Shigella strains].
Borisova EB
Mikrobiol Z; 2000; 62(1):64-72. PubMed ID: 11300086
[TBL] [Abstract][Full Text] [Related]
17. Duration of effects on clinical parameters and referred hyperalgesia in rats after abdominal surgery and multiple doses of analgesic.
Cooper DM; Hoffman W; Wheat N; Lee HY
Comp Med; 2005 Aug; 55(4):344-53. PubMed ID: 16158910
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of a new recombinant IpaC from Shigella dysenteriae type I in guinea pig as a vaccine candidate.
Malaei F; Hesaraki M; Saadati M; Ahdi AM; Sadraeian M; Honari H; Nazarian S
Iran J Immunol; 2013 Jun; 10(2):110-7. PubMed ID: 23811550
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain.
Ranallo RT; Thakkar S; Chen Q; Venkatesan MM
Vaccine; 2007 Mar; 25(12):2269-78. PubMed ID: 17229494
[TBL] [Abstract][Full Text] [Related]
20. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.
Oaks EV; Turbyfill KR
Vaccine; 2006 Mar; 24(13):2290-301. PubMed ID: 16364513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
